Can-Fite BioPharma (NYSE:CANF) Stock Price Up 0.3% – Time to Buy?

Posted by George Bondi on Jul 29th, 2026

Can-Fite BioPharma Ltd. (NYSE:CANF – Get Free Report) shares traded up 0.3% during trading on Tuesday . The company traded as high as $3.27 and last traded at $3.16. Approximately 20,962 shares were traded during trading, a decline of 98% from the average session volume of 1,143,556 shares. The stock had previously closed at $3.15.

Analysts Set New Price Targets

CANF has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $8.00 target price (up from $5.00) on shares of Can-Fite BioPharma in a research report on Thursday, July 2nd. D. Boral Capital raised Can-Fite BioPharma from a “hold” rating to a “buy” rating in a report on Wednesday, May 13th. Finally, Zacks Research raised Can-Fite BioPharma to a “hold” rating in a report on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.00.

View Our Latest Stock Report on Can-Fite BioPharma

Can-Fite BioPharma Price Performance

The stock’s 50 day simple moving average is $3.24 and its two-hundred day simple moving average is $3.58. The stock has a market cap of $2.07 million, a price-to-earnings ratio of -1.77 and a beta of 1.11.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Jane Street Group LLC bought a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 205,004 shares of the company’s stock, valued at approximately $41,000. Jane Street Group LLC owned 15.66% of Can-Fite BioPharma as of its most recent SEC filing. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).